Cilostazol
Phosphodiesterase-3 (PDE-3) Inhibitor- Drug Class
- Phosphodiesterase-3 (PDE-3) Inhibitor
- Mechanism of Action (MOA)
- Inhibits PDE-3 → ↑ cAMP → vasodilation and antiplatelet effect; improves claudication walking distance.
- Black Box Warning
- Contraindicated in heart failure of any severity — PDE-3 inhibitors decrease survival in patients with HF.
- Clinical Notes
- Symptomatic relief of intermittent claudication in PAD. Headache, palpitations, diarrhea. Do not use in any degree of heart failure.
- Source
- FDA label
Sources
Reviewed September 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
Used for
Same family
Got a pharmacology lecture that covers Cilostazol? Turn it into flashcards and board-style questions, free. Drop it on the home page
All pharmacology